These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 28969984)

  • 1. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
    Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
    Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
    J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
    Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
    CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving risk-stratification of natalizumab-associated PML.
    Tugemann B; Berger JR
    Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
    Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
    McGuigan C; Craner M; Guadagno J; Kapoor R; Mazibrada G; Molyneux P; Nicholas R; Palace J; Pearson OR; Rog D; Young CA
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):117-25. PubMed ID: 26492930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL; Chitnis T; Healy BC
    Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-JC virus antibody titres increase over time with natalizumab treatment.
    Raffel J; Gafson AR; Malik O; Nicholas R
    Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy.
    Borchardt J; Berger JR
    Mult Scler Relat Disord; 2016 Jul; 8():145-50. PubMed ID: 27456891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.